معرفی
Martin Bøgsted is a Professor at Aalborg University, serving as Center Director at Clinda (Center for Clinical Data Science) within the Clinical Institute of the Faculty of Health Sciences. With over 30 years of experience spanning academia, public sector, and industry, he leads significant research initiatives in clinical data science and artificial intelligence applications in healthcare.
His research interests span clinical data science, artificial intelligence, applied probability theory, statistics, and machine learning with applications in medicine, agriculture, and telecommunications. His fingerprint analysis reveals specialized expertise in Diffuse Large B-Cell Lymphoma (100%), B Cell research (74%), Multiple Myeloma (41%), Overall Survival analysis (40%), Malignant Neoplasm studies (34%), and Personalized Medicine (23%).
His recent publications demonstrate a strong focus on AI applications in healthcare, privacy-preserving synthetic data generation, clinical trial participation, and time-to-event prediction models. His work shows a clear trend toward integrating AI for personalized risk assessment and clinical interventions, with significant emphasis on ethical development of health data technologies.
Martin Bøgsted actively supervises master's and PhD students, with records indicating 14 PhD students supervised. He leads major research projects including SE3D (Synthetic health data: ethical development and deployment via deep learning approaches) funded by the Novo Nordisk Foundation (2024-2028) and ARISTOTELES (Integrating AI for Personalized Risk Assessment) (2023-2028).
He directs the Center for Clinical Data Science (CLINDA) at Aalborg University, which focuses on developing innovative infrastructure, artificial intelligence, and digital tools for multimodal data fusion and predictive modeling in the healthcare sector. His leadership extends to advisory roles including the Working Group for the National Genome Database and the Advisory Board for Research and Infrastructure at the Danish National Genome Center.
